4D Molecular Therapeutics (FDMT) Other Non-Current Assets (2019 - 2026)
4D Molecular Therapeutics (FDMT) reported Other Non-Current Assets of $9.9 million for Q1 2026, up 39.97% year-over-year from $7.0 million in Q1 2025, and up 7.29% quarter-over-quarter from $9.2 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Other Non-Current Assets (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 8 years of Other Non-Current Assets data on file, last reported at $9.9 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $9.9 million, up 39.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.9 million (up 39.97% YoY), and the FY2025 annual result was $9.2 million, up 115.63% from the prior year.
- Other Non-Current Assets climbed to $9.9 million in Q1 2026 per FDMT's latest filing, from $9.2 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $9.9 million in Q1 2026 and troughed at $682000.0 in Q3 2023.
- A 5-year average of $3.7 million and a median of $1.3 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets slumped 38.81% in 2024, then soared 813.49% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $1.1 million in 2022, then plunged by 36.67% to $684000.0 in 2023, then surged by 522.95% to $4.3 million in 2024, then jumped by 115.63% to $9.2 million in 2025, then grew by 7.29% to $9.9 million in 2026.
- Business Quant data shows FDMT's Other Non-Current Assets at $9.9 million in Q1 2026, $9.2 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | 9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.86 Mn |
| Dec 31, 2025 | 9.19 Mn |
| Sep 30, 2025 | 9.38 Mn |
| Jun 30, 2025 | 9.39 Mn |
| Mar 31, 2025 | 7.04 Mn |
| Dec 31, 2024 | 4.26 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.32 Mn |
| Mar 31, 2024 | 771,000.00 |
| Dec 31, 2023 | 684,000.00 |
| Sep 30, 2023 | 682,000.00 |
| Jun 30, 2023 | 1.08 Mn |
| Mar 31, 2023 | 1.26 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 1.05 Mn |
| Jun 30, 2022 | 963,000.00 |
| Mar 31, 2022 | 875,000.00 |
| Dec 31, 2021 | 602,000.00 |
| Sep 30, 2021 | 602,000.00 |
| Jun 30, 2021 | 602,000.00 |